FDA to fast-track three psychedelic drugs after Trump executive order

On Friday, the US Food and Drug Administration revealed it will issue priority review vouchers for three psychedelic drugs aimed at treating mental health disorders, a decision spurred by an executive order from President Donald Trump. The substances include psilocybin, found in magic mushrooms, intended for treatment-resistant depression, and methylene, related to MDMA, for post-traumatic stress disorder. Although the FDA did not disclose the names of the two companies researching psilocybin and the one focused on methylene, the vouchers are designed to accelerate review processes from months to weeks without ensuring approval. Trump's order, enacted last weekend, instructs federal agencies to facilitate access and relax regulations on psychedelics, which are still prohibited under federal law. This initiative aligns with increasing backing from Trump's supporters, such as combat veterans and advocates of the Make America Healthy Again movement led by Health Secretary Robert F. Kennedy Jr.